BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 19837762)

  • 21. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
    Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
    Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
    Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
    J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
    Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
    J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.
    Maddahi J; Czernin J; Lazewatsky J; Huang SC; Dahlbom M; Schelbert H; Sparks R; Ehlgen A; Crane P; Zhu Q; Devine M; Phelps M
    J Nucl Med; 2011 Sep; 52(9):1490-8. PubMed ID: 21849402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.
    Zanzonico PB; Finn R; Pentlow KS; Erdi Y; Beattie B; Akhurst T; Squire O; Morris M; Scher H; McCarthy T; Welch M; Larson SM; Humm JL
    J Nucl Med; 2004 Nov; 45(11):1966-71. PubMed ID: 15534070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
    Zechmann CM; Afshar-Oromieh A; Armor T; Stubbs JB; Mier W; Hadaschik B; Joyal J; Kopka K; Debus J; Babich JW; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1280-92. PubMed ID: 24577951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice.
    van Gog FB; Brakenhoff RH; Snow GB; van Dongen GA
    Cancer Immunol Immunother; 1997 Apr; 44(2):103-11. PubMed ID: 9177472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
    Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans.
    Doss M; Kolb HC; Zhang JJ; Bélanger MJ; Stubbs JB; Stabin MG; Hostetler ED; Alpaugh RK; von Mehren M; Walsh JC; Haka M; Mocharla VP; Yu JQ
    J Nucl Med; 2012 May; 53(5):787-95. PubMed ID: 22499613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
    Colnot DR; Wilhelm AJ; Cloos J; Roos JC; de Bree R; Quak JJ; Snow GB; van Dongen GA
    J Nucl Med; 2001 Sep; 42(9):1364-7. PubMed ID: 11535726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
    Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A
    Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport.
    Tolvanen T; Någren K; Yu M; Sutinen E; Havu-Aurén K; Jyrkkiö S; Asola M; Kotoneva E; Nuutila P; Minn H
    Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1178-84. PubMed ID: 16721566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
    Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
    J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.